Company / SG&A Expense
Nuvalent, Inc. SG&A Expense History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$107.3M
FY2025
5-year range
$10.3M / $107.3M
FY2021-FY2025
Trend
+71.5%
vs FY2024
Sector context
#109 of 213
Health Care
What the data says
At $107M, Nuvalent, Inc.'s sg&a expense ranks #105 of 213 in the Health Care sector. SG&A Expense has increased for 5 consecutive years, from $2M in FY2020 to $107M in FY2025.
Based on SEC 10-K filings.
$107M in FY2025 with a 5-year CAGR of +134.9%.
Increased from $36M to $107M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +68.6%
- 5-Year CAGR
- +134.9%
- 10-Year CAGR
- -
Sector benchmark
#105 of 213 in Health CareTop 49% of 213This company $107.3M Sector average $722.3M
▼
-85.1% below sector average
Key checks
Key Insights
- Nuvalent, Inc.'s sg&a expense has grown for 5 consecutive years.
- 5-year CAGR of +134.9%, indicating consistent growth.
- In FY2025, sg&a expense increased 71.5% year-over-year.
- Ranks #109 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 2.94 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $107.3M | +71.5% |
| FY2024 | $62.6M | +72.7% |
| FY2023 | $36.2M | +62.0% |
| FY2022 | $22.4M | +118.1% |
| FY2021 | $10.3M | +583.0% |
| FY2020 | $1.5M | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026